A Phase I Safety, Efficacy, and Pharmacokinetic Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Patients With AIDS or AIDS Related Complex

NCT00000710 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

42

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Didanosine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)